UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Archives

2024
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
2023
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
2022
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
2021
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
2020
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
2019
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
2018
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January

Nov

26 UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting

Read More Share:

|

Nov

20 Closing gaps in HS care through community engagement and scientific innovation

Read More Share:

|

Nov

20 UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa

Read More Share:

|

Nov

14 New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB’s Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis

Read More Share:

|

Nov

14 A Bright Future: Prioritizing Early Diagnosis, Maintenance, and Remissions in Rheumatology

Read More Share:

|

Categories

Archives

Nov

26

UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting

Nov

20

Closing gaps in HS care through community engagement and scientific innovation

Nov

20

UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa

Nov

14

New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB’s Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis

Nov

14

A Bright Future: Prioritizing Early Diagnosis, Maintenance, and Remissions in Rheumatology

Choose Country

UCB in the U.S.

Patients

Innovation

Sustainability

Newsroom

Contact

Categories

Archives

Nov

26

UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting

Nov

20

Closing gaps in HS care through community engagement and scientific innovation

Nov

20

UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa

Nov

14

New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB’s Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis

Nov

14

A Bright Future: Prioritizing Early Diagnosis, Maintenance, and Remissions in Rheumatology

Choose Country

UCB in the U.S.

Patients

Innovation

UCB Worldwide

Sustainability

Newsroom

Contact